Saudi Arabia's regulator for medicines, devices and food, set up in 2003. WHO rated it at maturity level 4 in 2023, and from January 2027 its target for reviewing a medicine already approved in the United States or the European Union is 30 or 60 working days.
WHO describes the SFDA as established in 2003 as the sole agency responsible for regulatory oversight of all medical products. In October 2023 WHO announced that the SFDA had reached maturity level 4 for medicines and vaccines under its Global Benchmarking Tool, after a benchmarking in November 2022, and quoted its Assistant Director-General calling it the first in the Eastern Mediterranean and the third worldwide to reach that level. The coordinates are an approximate Riyadh city point.
The SFDA's regulatory guidance for submissions and applications (version 1.0, issued October 2026) replaces its earlier framework and submission guideline and takes effect on 1 January 2027. Its performance targets, in working days of assessment and excluding validation and the registration committee's decision, are 205 for innovative products already registered with a stringent regulatory authority, 250 for those that are not, 160 for priority review, and 60 under the breakthrough medicine programme. The verification route (30 days) and abridged route (60 days) are for products already approved by the US FDA, the US Department of Agriculture and/or the EMA. Priority review also covers certain products made entirely in the Kingdom by a sole local manufacturer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/